Novartis shares rose over 1% premarket after the FDA approved Itvisma, the first gene-replacement therapy for SMA patients aged two and older. Phase III data showed improved or stabilised motor function with a single dose. The approval broadens Novartis gene therapy portfolio, supported by new rights to key AAV9 and recombinant AAV delivery platforms.